Background: Patients on dialysis undergoing surgery belong to a high-risk group. Only a few studies have evaluated the outcome of major thoracic surgical procedures in dialysis patients. We evaluated the outcomes of pulmonary resection for non-small cell lung cancer (NSCLC) in patients on hemodialysis (HD). Methods: Between 2008 and 2013, seven patients on HD underwent pulmonary resection for NSCLC at our institution. We retrospectively reviewed their surgical outcomes and prognoses. Results: The median duration of HD before surgery was 55.0 months. Five patients underwent lobectomy and two patients underwent wedge resection. Postoperative morbidity occurred in three patients, including pulmonary edema combined with pneumonia, cerebral infarction, and delirium. There were no instances of in-hospital mortality, although one patient died of intracranial bleeding 15 days after discharge. During follow-up, three patients (one patient with pathologic stage IIB NSCLC and two patients with pathologic stage IIIA NSCLC) experienced recurrence and died as a result of the progression of the cancer, while the remaining three patients (with pathologic stage I NSCLC) are alive with no evidence of disease. Conclusion: Surgery for NSCLC in HD patients can be performed with acceptable perioperative morbidity. Good medium-term survival in patients with pathologic stage I NSCLC can also be expected. Pulmonary resection seems to be the proper treatment option for dialysis patients with stage I NSCLC.
INTRODUCTION
Due to advances in dialysis techniques, the number of patients on long-term dialysis has been increasing [1] .
Moreover, a tendency for lung cancer to be detected earlier in dialysis patients has been reported, since these patients undergo more extensive follow-up and are monitored more closely by their doctors [2] . Therefore, it is reasonable to anticipate an increasing number of dialysis patients with lung cancer who require surgery.
Patients on dialysis undergoing surgery are a high-risk group, requiring careful perioperative management [3] 
METHODS
We performed a retrospective chart review on all patients who underwent pulmonary resection for NSCLC with curative In order to prevent bleeding, we administered a dose of desmopressin every six hours from the day of the operation until the third postoperative day. We sought to maintain preoperative hemoglobin levels ＞10 g/dL by injecting 2,000 U of erythropoietin subcutaneously twice a week. Additionally, red blood cell transfusion was performed during preoperative dialysis in patients whose hemoglobin level was ＜10 g/dL.
The decision to use adjuvant treatment was made by a multidisciplinary team based on the pathologic stage of the cancer, the general condition of the patient, and the presence of comorbidities.
Patients were evaluated with CT scans every three to four months for the first two years after surgery and every six months thereafter, and were also annually evaluated with PET/CT scans. When recurrence was suspected, we attempted to obtain unequivocal histological or radiological proof. In cases where follow-up was not performed, a telephone interview was conducted to determine outcomes.
RESULTS
There were five men and two women in our study, with a median age of 67 years (range, 62 to 70 years). The preoperative profiles of the patients are presented in Table 1 .
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There were no instances of in-hospital mortality, although the patient who suffered from cerebral infarction died of intracranial bleeding 1.1 months after the operation (15 days after discharge).
The patheologic results and medium-term outcomes are presented in Table 4 . In the other six patients, the median follow-up duration was 15.3 months (range, 12.9 to 57.5 months). Adjuvant radiotherapy was recommended for one patient diagnosed with parietal pleural invasion and two patients with N2 disease, but all three patients refused adjuvant treatment. During the follow-up period, these three patients experienced recurrence and died due to the progression of the cancer. The remaining three patients are alive with no evidence of disease. The overall survival rate was 43.0%.
DISCUSSION
Despite recent advances in treatments for lung cancer, the overall five-year survival for patients newly diagnosed with NSCLC is only 18% [6] , making lung cancer one of the deadliest carcinomas. Surgery remains the standard treatment modality for patients with early-stage NSCLC [7] . Therefore, decisions concerning operability have clear implications for achieving optimal treatment results.
Several studies have assessed the perioperative morbidity and mortality of CKD patients who are on HD and undergo surgery. The morbidity rate of patients who undergo non-cardiac surgery has been shown to vary from 7% to 64% [3, 8] .
The causes of higher morbidity rates were found to include difficulty in controlling fluid and electrolyte balance, a tendency towards increased bleeding, poor blood pressure control, and a high incidence of coronary artery disease [3, 9] .
A high morbidity rate after pulmonary resection in patients on HD has also been reported [1, 4, 5] . In addition to the complications involving fluid and electrolyte imbalance and bleeding that accompany HD, patients may be at increased risk of pulmonary complications after pulmonary resection.
Tsuchida et al. [5] reported a 43% incidence of pulmonary complications in patients on HD who underwent surgery.
Obuchi et al. [1] reported that the overall morbidity rate in their study was 27% (3 of 11 patients), and that two of those three patients experienced complications of pneumonia result-
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Generally, major pulmonary resection is accompanied by some pulmonary damage and edema. Patients on hemodialysis experience considerable difficulty in maintaining fluid balance, and are therefore more vulnerable to pulmonary edema.
Pulmonary edema can also trigger hypoxemia and pneumonia [5] . In the current study, we experienced one case of pulmonary edema combined with hospital-acquired pneumonia.
While the patient required intensive care and a prolonged hospital stay, he was successfully managed with CRRT and intravenous antibiotics.
In our center, we applied intrapulmonary doses to prevent bleeding and sought to maintain preoperative hemoglobin levels ＞10 mg/dL by injecting erythropoietin. Several studies have reported that desmopressin and erythropoietin help prevent postoperative bleeding in uremic patients, due to triggering an improvement in platelet function [10] [11] [12] [13] . Additionally, red blood cell transfusion was performed during preoperative dialysis in patients whose hemoglobin level was below the target. These strategies may be useful not only in minimizing bleeding, but also in reducing reduce blood transfusion requirements that can cause volume overload. In order to prevent pulmonary edema, fluid intake was restricted to 2 L/day.
Only one case of pulmonary edema was reported, and we succeeded in minimizing dialysis-related complications.
Although the overall complication rate was 43%, which is higher than that found in the general population [14] , it was possible to manage most complications through careful postoperative care, and all patients were discharged within 20 days of hospitalization. There was one case of short-term mortality, in which a patient who had a history of brain infarction before the operation died of traumatic brain hemorrhage after discharge. The traumatic brain hemorrhage was warfarin-related, not dialysis-related. Based on these results, we propose that preoperative dialysis itself is not a contraindication for pulmonary resection. However, since most patients on dialysis have other comorbidities, much consideration and effort should go into planning the operation and preventing postoperative complications.
Obuchi et al. [1] reported an overall five-year survival rate of 28.0% in the 11 patients in their study who underwent hemodialysis after surgery. Interestingly, four of the six deaths in their study were due to non-cancer causes, and the survival rate was 37.5% in patients with stage I disease. In the current study, the overall five-year survival rate was 34.3%. 
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